
SAB Biotherapeutics Investor Relations Material
Latest events
Access the full event backlog
Slides, Transcripts, and Reports from 12,000+ public companies
Latest reports from SAB Biotherapeutics Inc
Access all reports
SAB Biotherapeutics Inc. is a biotechnology company focused on developing immunotherapies using its proprietary DiversitAb platform. The company specializes in producing targeted, fully human polyclonal antibodies for infectious diseases, autoimmune disorders, and other conditions. SAB Biotherapeutics leverages genetically engineered cattle to generate scalable and high-potency antibody treatments. The company is headquartered in Sioux Falls, South Dakota, and its shares are listed on the NASDAQ.
Key slides for SAB Biotherapeutics Inc


Corporate Presentation
SAB Biotherapeutics Inc


Study Update
SAB Biotherapeutics Inc
Latest articles
)
Robert G. Hagstrom: Darwinian Investing and Multidisciplinary Wisdom
Robert G. Hagstrom, author of The Warren Buffett Way, explores how interdisciplinary thinking shapes his investing, from Adler's reading to Darwinian markets.
7 Feb 2025
)
Quartr Brings Stories Behind the Numbers to Light
Quartr simplifies access to IR material and puts qualitative insights and company narratives front and center.
3 Feb 2025
)
The Evolution of the IRO Role: Staying Informed and Strategic With Quartr Pro
Staying informed is critical for IROs. Quartr Pro simplifies gathering market insights and narrative positioning with unprecedented speed and precision.
3 Feb 2025
Ticker symbol
SABS
Country
🇺🇸 United States